| Serial Number | 79232578 |
| Word Mark | HYFC TECHNOLOGY |
| Filing Date | Wednesday, February 28, 2018 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, April 30, 2019 |
| Registration Number | 5736165 |
| Registration Date | Tuesday, April 30, 2019 |
| Mark Drawing | 3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, February 12, 2019 |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Disclaimer with Predetermined Text | "TECHNOLOGY" |
| Description of Mark | The mark consists of a stylized design consisting of two ovals connected by 5 lines to two more ovals that are divided, and are stacked above two other ovals. To the right of the stylized design are the letters "hyFc" stacked above the word "technology". |
| Goods and Services | Pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; pharmaceutical preparations for urogenital organs; pharmaceutical preparations for preventing and treating obesity; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for wounds; pharmaceutical preparations for activating cellular function; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for treating malignant tumours; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of infectious diseases; Synthetic peptides for pharmaceutical purposes for treating hypertension; Synthetic peptides for pharmaceutical purposes for the prevention of osteoporosis; Synthetic peptides for pharmaceutical purposes for the treatment of hormonal disorders and the prevention of osteoporosis; Synthetic peptides for pharmaceutical purposes for the treatment of eye diseases and conditions; Synthetic peptides for pharmaceutical purposes for the treatment of multiple sclerosis; Synthetic peptides for pharmaceutical purposes for treating diabetes; Synthetic peptides for pharmaceutical purposes for affecting metabolism; Synthetic peptides for pharmaceutical purposes for regulating the immune system; Synthetic peptides for pharmaceutical purposes for the treatment of viral diseases; Synthetic peptides for pharmaceutical purposes for affecting and treating urogenital organs; Synthetic peptides for pharmaceutical purposes for preventing and treating obesity; Synthetic peptides for pharmaceutical purposes for the treatment of bone diseases; Synthetic peptides for pharmaceutical purposes for wounds; Synthetic peptides for pharmaceutical purposes for activating cellular function; Synthetic peptides for pharmaceutical purposes for affecting digestive organs; Synthetic peptides for pharmaceutical purposes for the treatment of cardiovascular disease; Synthetic peptides for pharmaceutical purposes for treating malignant tumours; Synthetic peptides for pharmaceutical purposes for the treatment and prevention of cancer; Synthetic peptides for pharmaceutical purposes for treatment of viral and infectious diseases, for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of cancer; Synthetic peptides for pharmaceutical purposes for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of auto-immune diseases |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, June 1, 2018 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Genexine, Inc. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Party Name | Genexine, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Party Name | Genexine, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | KR |
| Event Date | Event Description |
| Thursday, May 28, 2020 | NEW REPRESENTATIVE AT IB RECEIVED |
| Friday, September 13, 2019 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Saturday, August 24, 2019 | FINAL DISPOSITION NOTICE SENT TO IB |
| Saturday, August 24, 2019 | FINAL DISPOSITION PROCESSED |
| Tuesday, July 30, 2019 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Monday, May 13, 2019 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Tuesday, April 30, 2019 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, February 12, 2019 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, February 12, 2019 | PUBLISHED FOR OPPOSITION |
| Friday, February 8, 2019 | NOTIFICATION PROCESSED BY IB |
| Wednesday, January 23, 2019 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, January 23, 2019 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, January 23, 2019 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, December 27, 2018 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Friday, December 28, 2018 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, December 27, 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, December 27, 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, December 27, 2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Saturday, July 14, 2018 | REFUSAL PROCESSED BY IB |
| Thursday, June 28, 2018 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Thursday, June 28, 2018 | REFUSAL PROCESSED BY MPU |
| Wednesday, June 20, 2018 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Tuesday, June 19, 2018 | NON-FINAL ACTION WRITTEN |
| Tuesday, June 12, 2018 | ASSIGNED TO EXAMINER |
| Tuesday, June 5, 2018 | APPLICATION FILING RECEIPT MAILED |
| Friday, June 1, 2018 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Thursday, May 24, 2018 | SN ASSIGNED FOR SECT 66A APPL FROM IB |